This combination product is strictly for laboratory research and is commonly employed in the following investigational areas:

Synergistic Weight Loss and Adiposity

The primary research application for the Cagrilintide/Semaglutide blend is the investigation of superior weight loss efficacy. Studies in diet-induced obese (DIO) models utilize this combination to quantify reductions in visceral adipose tissue and body weight that exceed the ceiling of GLP-1 monotherapy, attributed to the additive suppression of food intake.

Glycemic Control and Insulin Sensitivity

Researchers utilize this blend to study the dual regulation of glucose homeostasis. Semaglutide enhances glucose-dependent insulin secretion, while Cagrilintide suppresses postprandial glucagon secretion and slows gastric emptying. This dual mechanism is investigated for its potential to improve HbA1c and time-in-range metrics in models of Type 2 Diabetes.

Mechanisms of Satiety Signaling

This reagent is used as a chemical probe to dissect the cross-talk between the hindbrain (targeted by Cagrilintide) and the hypothalamus (targeted by Semaglutide). Experimental workflows involve mapping neuronal activation (c-Fos expression) in the nucleus of the solitary tract (NTS) and the arcuate nucleus to understand how these distinct pathways converge to regulate satiety.

Pathway / Mechanistic Context

The mechanism of action for the Cagrilintide/Semaglutide blend involves the simultaneous engagement of two distinct nutrient-sensing pathways.

• GLP-1 Pathway (Semaglutide): Activates GLP-1 receptors in the pancreas and brain, stimulating insulin release, reducing glucagon, and signaling satiety via the hypothalamus.
• Amylin Pathway (Cagrilintide): Agonizes the Amylin and Calcitonin receptors (AMY/CTR) in the area postrema. This signaling cascade delays gastric emptying and provides a distinct “fullness” signal independent of the GLP-1 pathway.
• Resulting Flux: The combination results in a “clamp” on energy intake by targeting both the homeostatic (energy need) and hedonic (reward) aspects of feeding behavior, leading to profound negative energy balance in experimental models.

Preclinical & Clinical Context

Published literature documents investigations of the Cagrilintide/Semaglutide combination (CagriSema) across multiple experimental models:

• Efficacy vs. Monotherapy: In Phase 2 investigational trials, the combination of 2.4mg Cagrilintide and 2.4mg Semaglutide demonstrated significantly greater weight loss (-15.6%) compared to Semaglutide (-5.1%) or Cagrilintide (-8.1%) alone in Type 2 Diabetes models.
• Safety Profile: Research indicates that the combination maintains a safety profile consistent with GLP-1 receptor agonists, with gastrointestinal transient effects being the most common observation in subject groups.
• Metabolic Synergy: Preclinical data suggests that the co-administration leads to superior improvements in lipid metabolism and inflammatory markers compared to individual components.

Form & Analytical Testing

This material is produced via robust chemical synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain compound integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity of both components.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Frias, J.P., Deenadayalan, S., Erichsen, L., et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet, 402(10403), 720–730. https://doi.org/10.1016/S0140-6736(23)01163-7
• Garvey, W.T., et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2502081
• Enebo, L., Berthelsen, K., Kankam, M., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet, 397(10286), 1736–1748. https://doi.org/10.1016/S0140-6736(21)00845-X
• Kruse, T., Hansen, J.L., Gerstenberg, M., et al. (2021). The long-acting amylin analogue cagrilintide reduces food intake and body weight in specific combination with semaglutide in varying ratios in rats. Diabetologia, 64(Suppl 1), S1–S362. https://doi.org/10.1007/s00125-021-05517-8
• Raun, K., et al. (2025). CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure. Nature Metabolism, 7, 1322–1329. https://doi.org/10.1038/s42255-025-01324-8

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.